翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03692 翰森制药

交易中 07-22 10:33:43

32.980

+0.420

+1.29%

最高33.320	最低31.980	成交量288.81万
今开32.180	昨收32.560	日振幅4.12%
总市值2,000亿	流通市值2,000亿	总股本60.64亿
成交额9,508万	换手率0.05%	流通股本60.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"翰森制药","latestPrice":32.98,"timestamp":1784687586829,"preClose":32.56,"halted":0,"volume":2888120,"delay":0,"changeRate":0.012899262899262732,"floatShares":6064000000,"shares":6064000000,"eps":1.0768919936024086,"marketStatus":"交易中","change":0.42,"latestTime":"07-22 10:33:43","open":32.18,"high":33.32,"low":31.98,"amount":95084422,"amplitude":0.041155,"askPrice":33,"askSize":12000,"bidPrice":32.92,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":1.0757213077900085,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1784692800000},"marketStatusCode":2,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":32.56,"dividendRate":0.013586,"openAndCloseTimeList":[[1784683800000,1784692800000],[1784696400000,1784707200000]],"volumeRatio":1.065772,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692","defaultTab":"news","newsList":[{"id":"2653378262","title":"国金证券：口服环肽成药性验证元年 百亿美元赛道启幕","url":"https://stock-news.laohu8.com/highlight/detail?id=2653378262","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653378262?lang=zh_cn&edition=full","pubTime":"2026-07-22 09:15","pubTimestamp":1784682933,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，口服环肽是继GLP-1之后多肽领域最具确定性的前瞻布局方向，建议重点关注在该领域具备核心平台技术与临床管线的领先企业。国金证券主要观点如下：成药性验证跨越，口服环肽范式正式确立2026年口服环肽赛道完成从\"科学概念\"到\"产业现实\"的关键跃迁，成药性被彻底验证。产业资本正以真金白银验证平台价值：2026年YTD全球环肽BD交易总额达61.7亿美元创历史新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0276","BK0183","BK0201","BK0188","BK1583","BK1191","BK1589","600109","03692","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134287176","title":"异动解读｜翰森制药盘中下跌3.33%，报32.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134287176","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134287176?lang=zh_cn&edition=full","pubTime":"2026-07-21 10:14","pubTimestamp":1784600073,"startTime":"0","endTime":"0","summary":"7月21日，翰森制药盘中下跌3.33%，报32.1港元/股，成交额7063.65万港元。翰森制药所在的制药行业中，板块整体走弱，个股中，石药集团跌1.88%，中国生物制药跌2.13%，恒瑞医药跌3.57%，凯莱英跌0.08%，先声药业跌0.46%。翰森制药集团有限公司是一家主要从事药品研发、生产及销售的投资控股公司，创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统疾病、代谢及其他治疗领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110687072","title":"异动解读｜翰森制药盘中上涨3.08%，制药板块集体回暖叠加近期多重利好支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=1110687072","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110687072?lang=zh_cn&edition=full","pubTime":"2026-07-20 09:59","pubTimestamp":1784512765,"startTime":"0","endTime":"0","summary":"7月20日，翰森制药盘中上涨3.08%，报32.62港元/股，成交额7988.15万港元。制药板块整体走强，石药集团涨3.83%，凯莱英涨3.41%，东阳光药涨3.36%，恒瑞医药涨3.0%，中国生物制药涨2.41%。多重研发及出海进展叠加板块回暖，推动股价反弹。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193832696","title":"异动解读｜翰森制药盘中下跌3.08%，报31.98港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193832696","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193832696?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:25","pubTimestamp":1784255147,"startTime":"0","endTime":"0","summary":"7月17日，翰森制药盘中下跌3.08%，报31.98港元/股，成交额9683.27万港元。翰森制药所在的制药行业中，板块整体走弱，个股中，石药集团跌4.65%，中国生物制药跌4.94%，恒瑞医药跌4.23%，凯莱英跌7.61%，绿叶制药跌4.96%。翰森制药集团有限公司是一家主要从事药品研发、生产及销售的投资控股公司，创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统疾病、代谢及其他治疗领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181258253","title":"异动解读｜翰森制药盘中上涨3.17%，多重利好催化延续强势","url":"https://stock-news.laohu8.com/highlight/detail?id=1181258253","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181258253?lang=zh_cn&edition=full","pubTime":"2026-07-16 09:30","pubTimestamp":1784165449,"startTime":"0","endTime":"0","summary":"7月16日，翰森制药盘中上涨3.17%，报33.84港元/股，成交额290.73万港元。消息面上，公司近期利好密集释放。7月14日，翰森制药公告旗下Avere Therapeutics将依据合并协议并入纳斯达克上市公司NextCure，同时集团已就环肽类IL-23受体拮抗剂HS-20118授予Avere全球独家许可，并参与Avere定向发行，推进公司国际化布局。多重研发及出海进展叠加，市场情绪持续升温。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651355064","title":"港股异动 | 翰森制药(03692)涨超4% 与Avere就IL-23达成全球独家许可 Avere将合并入NextCure","url":"https://stock-news.laohu8.com/highlight/detail?id=2651355064","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651355064?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:36","pubTimestamp":1784082995,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰森制药涨超4%，截至发稿，涨3.93%，报33.84港元，成交额2.85亿港元。消息面上，翰森制药发布公告，于2026年7月14日，Avere Therapeutics, Inc.与纳斯达克上市公司NextCure, Inc.订立合并协议，据此，Avere将合并入NextCure。此相关，该集团已就环肽类白介素-23受体拮抗剂HS-20118授予Avere独家许可；及已参与Avere发起的一轮包括其他投资者参与在内的定向发行。于2026年6月15日，该集团就该产品与Avere订立独家许可协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1191","BK1589","KCAI","03692","BK4585","BK4588","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106505090","title":"异动解读｜翰森制药盘中上涨3.5%，参股公司Avere将并入纳斯达克上市公司NextCure","url":"https://stock-news.laohu8.com/highlight/detail?id=1106505090","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106505090?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:55","pubTimestamp":1784080517,"startTime":"0","endTime":"0","summary":"7月15日，翰森制药盘中上涨3.5%，报33.7港元/股，成交额1.6亿港元。消息面上，公司于7月14日公告，旗下Avere Therapeutics将依据当日签署的合并协议并入纳斯达克上市公司NextCure Inc.，旨在整合双方在创新疗法领域的资源与专长，推进公司国际化布局。翰森制药集团有限公司是一家主要从事药品研发、生产及销售的投资控股公司，创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统疾病、代谢及其他治疗领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651350174","title":"翰森制药(03692.HK)参股公司Avere将合并入纳斯达克上市公司 NextCure","url":"https://stock-news.laohu8.com/highlight/detail?id=2651350174","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651350174?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:06","pubTimestamp":1784023583,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09834","BK1583","02834","BK1147","09086","07266","03455","BK1191","03086","07261","BK1589","07522","03692","03034","07568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151148378","title":"翰森制药旗下Avere Therapeutics将依据2026年7月14日签署的合并协议并入Nextcure","url":"https://stock-news.laohu8.com/highlight/detail?id=1151148378","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151148378?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:02","pubTimestamp":1784023337,"startTime":"0","endTime":"0","summary":"翰森制药旗下子公司Avere Therapeutics，将依据2026年7月14日正式签署的合并协议，并入生物技术公司Nextcure Inc.。此次合并旨在整合双方在创新疗法领域的资源与专长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK4139","BK1191","BK1583","NXTC","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162437","title":"港股异动 | 翰森制药(03692)涨超3% HS-20093治疗小细胞肺癌III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162437","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651162437?lang=zh_cn&edition=full","pubTime":"2026-07-13 09:56","pubTimestamp":1783907799,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰森制药涨超3%，截至发稿，涨3.38%，报32.94港元，成交额1.27亿港元。消息面上，7月10日，翰森制药发布公告，集团自主研发的B7-H3靶向抗体–药物偶联物HS20093，在用于经含铂治疗后进展或复发的小细胞肺癌患者关键性III期临床试验中达到总生存期的主要终点。ARTEMIS-008研究详细数据预计未来在国际肿瘤学术会议上予以公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK4588","BK1583","BK1191","BK4134","VXUS","KCAI","III","BK4585","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199377688","title":"异动解读｜翰森制药盘中上涨3.51%，核心ADC药物HS-20093小细胞肺癌三期试验达OS主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1199377688","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199377688?lang=zh_cn&edition=full","pubTime":"2026-07-13 09:42","pubTimestamp":1783906943,"startTime":"0","endTime":"0","summary":"7月13日，翰森制药盘中上涨3.51%，报32.88港元/股，成交额7565.69万港元。消息面上，公司于7月10日盘后公告，自研B7-H3靶向ADC药物HS-20093在治疗经含铂方案后进展或复发的小细胞肺癌患者的关键性III期临床试验中达到总生存期主要终点，与托泊替康相比显示出具有统计学意义和临床意义的改善，次要终点无进展生存期亦观察到一致获益。该研究系全球首个在小细胞肺癌III期临床中证实B7-H3 ADC带来显著OS获益的试验，公司将推进新药上市申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650157207","title":"翰森制药的出海，不靠声量","url":"https://stock-news.laohu8.com/highlight/detail?id=2650157207","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650157207?lang=zh_cn&edition=full","pubTime":"2026-07-12 11:21","pubTimestamp":1783826507,"startTime":"0","endTime":"0","summary":"一次三期成功，兑现的是走了十年的路。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3776708","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1589","03692","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159250575","title":"翰森制药宣布HS-20,093在三期小细胞肺癌试验中达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1159250575","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159250575?lang=zh_cn&edition=full","pubTime":"2026-07-10 23:26","pubTimestamp":1783697165,"startTime":"0","endTime":"0","summary":"翰森制药集团有限公司宣布，其候选药物HS-20,093在针对小细胞肺癌的三期临床试验中，成功达到了预设的主要研究终点。\n这一积极成果标志着该药物在关键研发阶段取得了重要进展。小细胞肺癌是一种侵袭性强、治疗选择有限的恶性肿瘤，新疗法的开发具有显著的临床需求。\n公司后续将进行更全面的数据分析，并计划与监管机构沟通，以推进该药物的上市进程。此次试验结果的公布，预计将为翰森制药在肿瘤治疗领域的布局增添重要砝码。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK1191","BK1583","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148062271","title":"翰森制药B7-H3靶向ADC HS-20093三期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1148062271","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148062271?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:41","pubTimestamp":1783683679,"startTime":"0","endTime":"0","summary":"2026年7月10日，翰森制药集团有限公司公告称，其自主研发的B7-H3靶向抗体-药物偶联物HS-20093在治疗经含铂方案后进展或复发的小细胞肺癌患者的关键性III期临床试验中，已达到总生存期的主要终点。翰森制药表示，将尽快与监管机构沟通，推进HS-20093在中国的新药上市申报。本公告由翰森制药董事会主席钟慧娟于2026年7月10日签署发布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130235478","title":"异动解读｜翰森制药盘中上涨3.08%，创新药支付改革催化叠加板块联动走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1130235478","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130235478?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:07","pubTimestamp":1783649274,"startTime":"0","endTime":"0","summary":"7月10日，翰森制药盘中上涨3.08%，报32.12港元/股，成交额6689.21万港元。消息面上，创新药板块集体走强，制药行业个股普涨，凯莱英涨4.86%、石药集团涨3.57%、中国生物制药涨3.4%、恒瑞医药涨3.33%，板块联动效应显著。公司层面，近期管线催化密集释放，减重药奥莱泊肽及HS-10568注射液NDA相继获受理，HS-20136-2注射液获批两项临床试验，创新药商业化进程加速推进。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166884641","title":"异动解读｜翰森制药盘中下跌3.05%，报31.14港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166884641","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166884641?lang=zh_cn&edition=full","pubTime":"2026-07-09 13:32","pubTimestamp":1783575120,"startTime":"0","endTime":"0","summary":"7月9日，翰森制药盘中下跌3.05%，报31.14港元/股，成交额2.65亿港元。翰森制药所在的制药行业中，板块个股涨跌分化，中国生物制药涨3.32%，凯莱英涨2.37%，石药集团跌0.38%，恒瑞医药跌0.85%，联邦制药跌2.92%。翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司，创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统疾病、代谢及其他治疗领域，主要在国内市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147405619","title":"异动解读｜翰森制药盘中上涨3.07%，创新药板块集体反弹叠加管线催化延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1147405619","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147405619?lang=zh_cn&edition=full","pubTime":"2026-07-08 09:49","pubTimestamp":1783475380,"startTime":"0","endTime":"0","summary":"7月8日，翰森制药盘中上涨3.07%，报33.68港元/股，成交额9595.53万港元。消息面上，制药板块今日集体走强，中国生物制药涨5.81%、恒瑞医药涨3.18%、海西新药涨3.55%，板块联动效应显著。此前7月2日公司公告自主研发的1类新药HS-20136-2注射液获NMPA签发两项临床试验批准通知书，分别用于2型糖尿病及体重管理临床试验，创新管线催化持续释放。叠加此前减重药奥莱泊肽及HS-10568注射液NDA相继获受理，公司创新药商业化进程加速推进，市场情绪延续修复。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179139774","title":"异动解读｜翰森制药盘中下跌3.24%，报32.44港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179139774","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179139774?lang=zh_cn&edition=full","pubTime":"2026-07-07 09:46","pubTimestamp":1783388781,"startTime":"0","endTime":"0","summary":"7月7日，翰森制药盘中下跌3.24%，报32.44港元/股，成交额7382.15万港元。翰森制药所在的制药行业中，板块整体走弱，个股中，石药集团跌3.16%，恒瑞医药跌2.80%，中国生物制药跌2.18%，凯莱英跌2.00%，绿叶制药跌1.97%。翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司，创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统疾病、代谢及其他治疗领域，主要在国内市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106013127","title":"异动解读｜翰森制药盘中上涨3.74%，创新管线催化密集释放叠加制药板块集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1106013127","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106013127?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:56","pubTimestamp":1783306606,"startTime":"0","endTime":"0","summary":"7月6日，翰森制药盘中上涨3.74%，报34.96港元，成交额2.87亿港元。消息面上，公司近期创新管线利好密集释放。7月2日晚间公告，自主研发的1类新药HS-20136-2注射液获国家药品监督管理局签发的两项临床试验批准通知书，分别用于\"2型糖尿病\"及\"体重管理\"临床试验。此前公司减重药奥莱泊肽及HS-10568注射液NDA相继获受理，创新药商业化进程加速推进。同时制药板块今日集体走强，中国生物制药涨11.18%、石药集团涨6.12%、恒瑞医药涨3.92%，板块联动效应显著。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125530726","title":"翰森制药6月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1125530726","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125530726?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:57","pubTimestamp":1783069037,"startTime":"0","endTime":"0","summary":"翰森制药集团有限公司于2026年7月3日发布的月度报告显示，截至2026年6月30日，公司注册股本及已发行股份数均保持稳定，期间未有新增发行、购回或注销股份活动。根据公告，翰森制药的法定/注册股本维持在20,000,000,000股，面值每股0.00001港元，法定/注册股本总额约200,000港元。本月末已发行普通股股数为6,064,150,070股，与上月末持平，库藏股数量仍为0股。本月内可换股债券的发行总额和转股状况未发生变化。公告由联席公司秘书郭颖女士于2026年7月3日签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0937},{"period":"3month","weight":-0.173},{"period":"6month","weight":-0.1873},{"period":"1year","weight":-0.0812},{"period":"ytd","weight":-0.0918}],"compareEarnings":[{"period":"1week","weight":0.0325},{"period":"1month","weight":0.0505},{"period":"3month","weight":-0.0394},{"period":"6month","weight":-0.0562},{"period":"1year","weight":0.0055},{"period":"ytd","weight":-0.0194}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品包括阿美乐、豪森昕福、迈灵达、孚来美、恒沐、昕越、圣罗莱等产品。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统（CNS）疾病、代谢及其他治疗领域。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.002557},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.012842},{"month":3,"riseRate":0.428571,"avgChangeRate":0.023369},{"month":4,"riseRate":0.571429,"avgChangeRate":0.033966},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.005203},{"month":6,"riseRate":0.571429,"avgChangeRate":0.039397},{"month":7,"riseRate":0.625,"avgChangeRate":0.013003},{"month":8,"riseRate":0.714286,"avgChangeRate":0.018961},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.033022},{"month":10,"riseRate":0.142857,"avgChangeRate":0.0016},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063448},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016866}],"exchange":"SEHK","name":"翰森制药","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰森制药,03692,翰森制药股票,翰森制药股票老虎,翰森制药股票老虎国际,翰森制药行情,翰森制药股票行情,翰森制药股价,翰森制药股市,翰森制药股票价格,翰森制药股票交易,翰森制药股票购买,翰森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}